Data indicates benefits of Precision Spectra SCS in Back Pain-Boston Scientific

New retrospective data evaluating the Boston Scientific's Precision Spectra Spinal Cord Stimulator (SCS) System demonstrate that the device provided sustained, highly significant relief of Low Back Pain 12 months after implantation. At 12 months post-implantation, results demonstrate a sustained and significant reduction in overall pain measured on the 0-10 numeric rating scale (NRS) was reported, from an average baseline score of 7.17, to an average score of 2.96 at 12 months post-implantation (N= 178). In patients with only low back pain (N= 73), a sustained and significant reduction of low back pain (measured on the 0-10 NRS scale) was reported, from an average baseline score of 7.21 to an average of 3.17 at 12 months post-implantation. In patients with severe low back pain (N= 41, baseline score of 8 or greater measured on the 0-10 NRS scale), sustained and significant reduction in pain was reported, from an average score of 8.60 at baseline to 2.87 at 12 months post-implantation.

This cohort will be followed through the 24-month interval. Results from the PRO Study are being presented at the 18th North American Neuromodulation Society (NANS) meeting. Other studies being presented include ACCELERATE, a prospective multicenter trial evaluating conventional high-rate (10 kHz) spinal cord stimulation in the management of chronic, intractable pain, and WHISPER, a prospective multicenter trial evaluating the use of sub-perception multiple independent current control (MICC) SCS at up to 1.2 kHz.